Back to top
more

Apollo Endosurgery, Inc. (APEN)

(Delayed Data from NSDQ)

$3.54 USD

3.54
5,491

-0.28 (-7.33%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.95 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Has AMN Healthcare Services (AMN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AMN Healthcare Services (AMN) and Apollo Endosurgery, Inc. (APEN) have performed compared to their sector so far this year.

Apollo Endosurgery, Inc. (APEN) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Apollo Endosurgery, Inc. (APEN) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

How Much Upside is Left in Apollo Endosurgery, Inc. (APEN)? Wall Street Analysts Think 35%

by Zacks Equity Research

The consensus price target hints at a 35.4% upside potential for Apollo Endosurgery, Inc. (APEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Apollo Endosurgery, Inc. (APEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 35.29% and 17.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Apollo Endosurgery, Inc. (APEN) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apollo Endosurgery, Inc. (APEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 10.53% and 17.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Apollo Endosurgery, Inc. (APEN) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Ranked Momentum Stocks to Buy for April 14th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 14th

Sanghamitra Saha headshot

5 ETFs & Stocks to Profit From One-Year High U.S. Inflation

by Sanghamitra Saha

The annual U.S. inflation for the month of November beat expectations and put these ETFs and stocks in focus.

Apollo Endosurgery (APEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Apollo Endosurgery (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apollo Endosurgery (APEN) Q3 Earnings Preview: What's in the Cards?

by Zacks Equity Research

Apollo Endosurgery (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Second Sight Medical (EYES) in Focus: Stock Moves 12.1% Higher

by Zacks Equity Research

Second Sight Medical (EYES) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.

    Cogentix Medical (CGNT) in Focus: Stock Moves 6.6% Higher

    by Zacks Equity Research

    Cogentix Medical (CGNT) was a big mover last session, as the company saw its shares nearly 7% on the day amid huge volumes.

      The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx

        4 Top-Ranked Growth Stocks in MedTech Under $20

        by Zacks Equity Research

        In the wake of the turbulent political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable picks.